Meeting
2021 ASCO Annual Meeting
A methodology for the extraction and analysis of real-world radiographic and electronic medical record data to reconstruct treatment arms of historical prostate cancer clinical trials.
Authors
William David Lindsay
Oncora Medical, Inc., Philadelphia, PA
William David Lindsay , Christopher A. Ahern , Aaron Kamauu , Robert Wilder , Karen Chagin , Timmothy Taps
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5033)
DOI
10.1200/JCO.2021.39.15_suppl.5033
Abstract #
5033
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.
First Author: Nicholas Moffett
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2021 Genitourinary Cancers Symposium
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao